Agreement

Agreement. Shall have the meaning set forth in the Stock Option Grant Notice.

Agreement. Stock Unit Award Agreement

Agreement. This Investor Rights Agreement (this "Agreement"), dated as of July 11, 2019, is entered into by and among Jones Soda Co., a Washington corporation (the "Company"), Heavenly RX Ltd., a British Columbia corporation ("Investor"), and each of the shareholders listed on Schedule A hereto (collectively, the "Shareholders").

Agreement. Has the meaning set forth in the Preamble and includes all Transition Services Schedules attached hereto.

Agreement. Shall mean that certain [* * *] Agreement between Eyemax and [* * *] dated [* * *], as amended to date.

Agreement. Shall mean [* * *].

Agreement. Have the meaning in the preamble.

Agreement. This Dealer Manager and Solicitation Agent Agreement

Agreement. THIS LICENSE AGREEMENT ('Agreement') is made and entered into as of this 14th day of November, 2009 ('Effective Date') by and between The Washington University, a corporation established by special act of the Missouri General Assembly, approved February 22, 1853 and acts amendatory thereto, having its principal office at One Brookings Drive, St. Louis, Missouri 63130 ('WUSTL'), and Castle Biosciences, Inc., a corporation, ('Licensee') having a principal office at 2014 San Miguel Drive,... Friendswood, Texas 77546 and the following correspondence address: Castle Biosciences Attn: Derek Maetzold 2014 San Miguel Drive, Friendswood, Texas 77546 Tel No: 281-796-9032 Fax No: 866-431-2924 License Issue Fee: a non-refundable, non-creditable fee of [***] dollars ($[***]). [***] dollars ($[***] within [***] ([***]) days of execution of the Agreement, and [***] dollars ($[***]) within [***] ([***]) months of the Effective Date of the Agreement.) License Maintenance Fee: [***] dollars ($[***] per year upon start of the [***]anniversary from the Effective Date of the Agreement and each subsequent year thereafter until the First Commercial Sale. Milestones and Payments: For each 510K approval or PMA (Premarket Approval) or PMN (Premarket Notification): [***] dollars ($[***]) per approval no later than [***] ([***]) days from approval. For issuance of the first US patent: [***] dollars ($[***]) no later than [***] ([***]) days from issuance of such patent For issuance of the first foreign patent: [***] dollars ($[***]) no later than [***] ([***]) days from issuance of such patent. Royalty Rate: a. Patent Royalty Rate [***]-percent ([***]%) of Net Sales (Licensee, Affiliate or Sublicensees) b. Non-Patent Royalty Rate [***]-percent ([***]%) of Net Sales (Licensee, Affiliate or Sublicensees) Minimum Royalty: Commencing with the first Calendar Half following the Calendar Half when the First Commercial Sale occurs and continuing thereafter throughout the last to expire of a Valid Claim of the Patent Rights, Licensee agrees to pay WUSTL a minimum royalty equal to the Minimum Royalty for each Calendar Half as an advance against the royalties due under Section 5.3.1. Such Minimum Royalties shall be due on January 31 and July 31 of each Calendar Half. Period after Commercial Sale Minimum Royalty First Four Calendar Halves $[***] per Calendar Half Fifth, Sixth, Seventh, and Eighth Calendar Halves $[***] per Calendar Half Ninth and Each Subsequent Calendar Half thereafter $[***] per Calendar Half Sublicensee Revenue percentage: [***]% of the Sublicensee Revenue [***] = Certain Confidential Information Omitted Patents: Patent Title: Method For Predicting Risk Of Metastasis Application Number: [***] Previous and ongoing patent expenses to be paid by Licensee pursuant to the terms of Section 9.2 hereof. A sum of [***] dollars and [***] cents ($[***]) in past patent expenses will be paid by the Licensee no later than [***] ([***]) days from the Effective Date of this Agreement. Field: Medical diagnostics and prognostics in the field of melanoma. Territory: Worldwide. View More

Agreement. The Note Purchase Agreement or other agreement pursuant to which the Note is issued, including all exhibits thereto and all related Transaction Documents as defined therein